Clinical Trials Logo

Clinical Trial Summary

The children who will undergo OLV (one lung ventilation) through general anesthesia will be divided into two groups: The first will be intravenous infusion of dexmedetomidine at 0.4 mcg / kg / hour, and the second will be intravenous infusion of normal saline. We will take three samples of arterial blood gas (ABG) during the surgery at certain times. We record the hemodynamic values, PaO2, and calculate the value of the shunt Qs / Qt.


Clinical Trial Description

Lung isolation or one lung ventilation OLV means the mechanical separation of the lungs with independent ventilation of one lung from the other, in order to provide a suitable space for the work of the surgeon, and to protect a healthy lung from bleeding or edema caused by lung damage. OLV can lead to a mismatch in the ventilation / perfusion (V / Q) ratio resulting in increased intrapulmonary shunt as well as hypoxia. Hypoxic pulmonary vasoconstriction HPV is the most important preventive mechanism against hypoxemia, as blood flow moves from the unventilated lung to the ventilated lung to maintain an adequate arterial oxygen transport rate, HPV is a defense mechanism against hypoxia as it reduces pulmonary shunt. So that there is less oxygen drop than expected. HPV reaches its maximum effect in 15 minutes, resulting in decreased pulmonary shunt, homogenization of ventilation / perfusion ratio, and improved oxygen delivery. HPV is affected by various factors: changes in pulmonary pressure, alkalosis, vasodilators, anesthetic agents etc. Among these factors, anesthetic inhaled gases have the greatest effect on HPV. Pulmonary shunt: It is the sum of the physiological shunt (poorly ventilated air sacs) and the anatomical shunt and the pulmonary shunt fraction (Qs/Qt) is calculated from the equation Qs/Qt = (CcO2 - CaO2)/(CcO2 - CvO2) Qs: blood flow through the shunt, Qt : total blood flow, Cc'O2 : pulmonary capillary content of O2, CaO2 : arterial content of O2, CvO2 : venous mixed content of O2 100% O2 test: often performed in a cardiac catheterization lab, operating room, or ICU, the patient breathes 100% O2 until nitrogen is washed out from their lungs (20 minutes). The oxygen concentration even in poorly ventilated units will approach 100%. This means that the partial pressure and blood saturation are equal in the poorly ventilated and well-ventilated alveolar units, thus the physiological pulmonary shunt is canceled and the anatomical pulmonary shunt remains After lung isolation and OLV application, we perform anesthesia maneuvers on the ventilator and adjust the applied ventilators in order to maintain adequate oxygenation of the patient: increased PEEP, increased FLOW, increased tidal volume Vt, increased Pmax, increased FiO2, thus eliminating the physiological pulmonary shunt and the anatomical pulmonary shunt remains, in total we apply 100% O2 testing. Dexmedetomidine is a selective agonist for α2 receptors whose affinity for α2 receptors is eight times more than clonidine. At a dose of 0.3 mg / kg it activates protein G and inhibits norepinephrine secretion. When given in larger doses or infusion it stimulates the peripheral α2 receptors; It reduces the levels of norepinephrine in the plasma by more than 90%, thus reducing the cells' metabolism and their need for oxygen.Sympathetic blocker: Reduces heart rate, blood pressure and oxygen consumption of the heart muscle. Studies have shown that alpha-adrenergic blockade abolished pulmonary vasoconstriction that responds to norepinephrine but not to hypoxia. That is, it does not affect the blood supply and HPV of the unventilated lung, widens the blood vessels of the ventilated lung, and reduces the anesthetic requirements (affecting HPV); Reduces 30% of the need for propofol; It reduces desflurane concentration and its subsequent inhibitory effect on HPV. It may also lead to transient increases in pulmonary artery pressure related to its direct effects on vascular smooth muscle through alpha-adrenergic receptors. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04932746
Study type Interventional
Source Damascus University
Contact
Status Completed
Phase N/A
Start date March 1, 2021
Completion date February 1, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04072419 - Application of Enhanced Recovery After Surgery for Congenital Esophageal Atresia During Perioperative Period
Withdrawn NCT03127345 - Omega 3 Fatty Acid Treatment for Pediatric Musculoskeletal Health Phase 2
Completed NCT00226044 - Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants. Phase 3
Completed NCT03615495 - Flourish™ Pediatric Esophageal Atresia
Recruiting NCT05995171 - Long Term Outcome of Easophageal Atresia : Transmics Profiles in Adolescence
Completed NCT04901546 - Esophageal Atresia: a Natural Experiment of the Effects of Oral Inoculation on the Gut Microbiome N/A
Recruiting NCT03730454 - Transanastomotic Tube for Proximal Esophageal Atresia With Distal Tracheoesophageal Fistula Repair N/A
Recruiting NCT03455881 - Phenotypic and Genetic Assessment of Tracheal and Esophageal Birth Defects in Patients
Completed NCT05527873 - Respiratory Complications of Operated Esophageal Atresia in Children
Not yet recruiting NCT04259528 - Endoscopic Ultrasound Findings in Esophageal Atresia Following Surgical Repair N/A
Recruiting NCT06073158 - Molecular Signatures of Esophageal Atresia N/A
Not yet recruiting NCT03999008 - Oral Viscous Budesonide in Anastomotic Stricture After Esophageal Atresia Repair (OVB in EA) N/A
Completed NCT03415893 - High-resolution Esophageal Manometry N/A
Not yet recruiting NCT03023865 - Individualized Management for Long Gap Esophageal Atresia N/A
Recruiting NCT02883725 - National Register of Oesophageal Atresia
Not yet recruiting NCT04136795 - Evaluation of the Respiratory Impact After Conventional or Minimally Invasive Esophageal Atresia Surgery
Recruiting NCT03619408 - Management of Esophagitis Following Repair of Esophageal Atresia
Completed NCT05129930 - Fluid Overload and Pulmonary Function
Completed NCT02033772 - Prospective Data Collection of Patients < 6 Months of Age Undergoing Thoracoscopic Surgery N/A
Recruiting NCT03767673 - Cardiorespiratory Performance and Pulmonary Microbiome in Patients After Repair of Esophageal Atresia N/A